, Australia The fungus is highly toxic, and is responsible for the majority of fatal
mushroom poisonings worldwide. Its biochemistry has been researched intensively for decades, On average, one person dies a year in North America from death cap ingestion. The toxins of the death cap mushrooms primarily target the liver, but other organs, such as the kidneys, are also affected. Symptoms of death cap mushroom toxicity usually occur 6 to 12 hours after ingestion. Symptoms of ingestion of the death cap mushroom may include nausea and vomiting, which is then followed by
jaundice, seizures, and coma, which will lead to death. The mortality rate of ingestion of the death cap mushroom is believed to be around 10–30%. Some authorities strongly advise against putting suspected death caps in the same basket with fungi collected for the table and to avoid even touching them. Furthermore, the toxicity is not
reduced by cooking, freezing, or drying. Poisoning incidents usually result from errors in identification. Recent cases highlight the issue of the similarity of
A. phalloides to the edible paddy straw mushroom (
Volvariella volvacea), with East and Southeast Asian immigrants in Australia and the
West Coast of the U.S. falling victim. In an episode in
Oregon, four members of a Korean family required
liver transplants.
Detection The so-called
Meixner test is used to detect the presence of amatoxins in a sample. The test gives
false positive results for
psilocin,
psilocybin, and
5-substituted tryptamines.
Signs and symptoms Death caps have been reported to taste pleasant. This, coupled with the delay in the appearance of symptoms—during which time internal organs are being severely, sometimes irreparably, damaged—makes them particularly dangerous. Initially, symptoms are
gastrointestinal in nature and include
colicky abdominal pain, with watery
diarrhea,
nausea, and
vomiting, which may lead to
dehydration if left untreated, and, in severe cases,
hypotension,
tachycardia,
hypoglycemia, and
acid–base disturbances.
Kidney failure (either secondary to severe
hepatitis or caused by direct toxic kidney damage It is noticed that after up to 24 hours have passed, the symptoms seem to disappear and the person might feel fine for up to 72 hours. Symptoms of liver and kidney damage start 3 to 6 days after the mushrooms were eaten, with the considerable increase of the transaminases. Mushroom poisoning is more common in Europe than in North America. Up to the mid-20th century, the mortality rate was around 60–70%, but this has been greatly reduced with advances in medical care. A review of death cap poisoning throughout Europe from 1971 to 1980 found the overall mortality rate to be 22.4% (51.3% in children under ten and 16.5% in those older than ten). This was revised to around 10–15% in surveys reviewed in 1995.
Treatment Consumption of the death cap is a
medical emergency requiring hospitalization. The four main categories of therapy for poisoning are preliminary medical care, supportive measures, specific treatments, and liver transplantation. Preliminary care consists of gastric decontamination with either
activated carbon or
gastric lavage; due to the delay between ingestion and the first symptoms of poisoning, it is common for patients to arrive for treatment many hours after ingestion, potentially reducing the efficacy of these interventions. Supportive measures are directed towards treating the dehydration which results from fluid loss during the gastrointestinal phase of intoxication and correction of
metabolic acidosis, hypoglycemia,
electrolyte imbalances, and impaired coagulation. Some evidence indicates intravenous
silibinin, an extract from the
blessed milk thistle (
Silybum marianum), may be beneficial in reducing the effects of death cap poisoning. A long-term clinical trial of intravenous silibinin began in the US in 2010. Silibinin prevents the uptake of amatoxins by
liver cells, thereby protecting undamaged liver tissue; it also stimulates DNA-dependent RNA polymerases, leading to an increase in RNA synthesis. According to one report based on a treatment of 60 patients with silibinin, patients who started the drug within 96 hours of ingesting the mushroom and who still had intact kidney function all survived. As of February 2014 supporting research has not yet been published.
SLCO1B3 has been identified as the human hepatic uptake transporter for amatoxins; moreover, substrates and inhibitors of that protein—among others
rifampicin, penicillin, silibinin,
antamanide,
paclitaxel,
ciclosporin and
prednisolone—may be useful for the treatment of human amatoxin poisoning.
N-Acetylcysteine has shown promise in combination with other therapies. Animal studies indicate the amatoxins deplete hepatic
glutathione; N-acetylcysteine serves as a glutathione precursor and may therefore prevent reduced glutathione levels and subsequent liver damage. None of the antidotes used have undergone prospective,
randomized clinical trials, and only anecdotal support is available. Silibinin and N-acetylcysteine appear to be the therapies with the most potential benefit. Other methods of enhancing the elimination of the toxins have been trialed; techniques such as
hemodialysis,
hemoperfusion,
plasmapheresis, and
peritoneal dialysis have occasionally yielded success, but overall do not appear to improve outcome. This is a complicated issue, however, as transplants themselves may have significant
complications and mortality; patients require long-term
immunosuppression to maintain the transplant. Evidence suggests, although survival rates have improved with modern medical treatment, in patients with moderate to severe poisoning, up to half of those who did recover suffered permanent liver damage. A follow-up study has shown most survivors recover completely without any
sequelae if treated within 36 hours of mushroom ingestion. ==Notable victims==